Bioassay Development for Bispecific Antibodies—Challenges and Opportunities

Antibody therapeutics are expanding with promising clinical outcomes, and diverse formats of antibodies are further developed and available for patients of the most challenging disease areas. Bispecific antibodies (BsAbs) have several significant advantages over monospecific antibodies by engaging t...

Full description

Bibliographic Details
Main Authors: Ames C. Register, Somayeh S. Tarighat, Ho Young Lee
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/10/5350
id doaj-28c5d39819af41988dd5624d86c3949d
record_format Article
spelling doaj-28c5d39819af41988dd5624d86c3949d2021-06-01T00:29:27ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-01225350535010.3390/ijms22105350Bioassay Development for Bispecific Antibodies—Challenges and OpportunitiesAmes C. Register0Somayeh S. Tarighat1Ho Young Lee2Biological Technologies, Department of Analytical Development and Quality Control, Genentech—A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080, USACell Therapy Analytical Development, Department of Cell Therapy Engineering and Development, Genentech—A Member of the Roche Group, South San Francisco, CA 94080, USACell Therapy Analytical Development, Department of Cell Therapy Engineering and Development, Genentech—A Member of the Roche Group, South San Francisco, CA 94080, USAAntibody therapeutics are expanding with promising clinical outcomes, and diverse formats of antibodies are further developed and available for patients of the most challenging disease areas. Bispecific antibodies (BsAbs) have several significant advantages over monospecific antibodies by engaging two antigen targets. Due to the complicated mechanism of action, diverse structural variations, and dual-target binding, developing bioassays and other types of assays to characterize BsAbs is challenging. Developing bioassays for BsAbs requires a good understanding of the mechanism of action of the molecule, principles and applications of different bioanalytical methods, and phase-appropriate considerations per regulatory guidelines. Here, we review recent advances and case studies to provide strategies and insights for bioassay development for different types of bispecific molecules.https://www.mdpi.com/1422-0067/22/10/5350bispecific antibodiesbioassaysmechanisms of actionbinding assayspotency assays
collection DOAJ
language English
format Article
sources DOAJ
author Ames C. Register
Somayeh S. Tarighat
Ho Young Lee
spellingShingle Ames C. Register
Somayeh S. Tarighat
Ho Young Lee
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
International Journal of Molecular Sciences
bispecific antibodies
bioassays
mechanisms of action
binding assays
potency assays
author_facet Ames C. Register
Somayeh S. Tarighat
Ho Young Lee
author_sort Ames C. Register
title Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
title_short Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
title_full Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
title_fullStr Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
title_full_unstemmed Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
title_sort bioassay development for bispecific antibodies—challenges and opportunities
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-05-01
description Antibody therapeutics are expanding with promising clinical outcomes, and diverse formats of antibodies are further developed and available for patients of the most challenging disease areas. Bispecific antibodies (BsAbs) have several significant advantages over monospecific antibodies by engaging two antigen targets. Due to the complicated mechanism of action, diverse structural variations, and dual-target binding, developing bioassays and other types of assays to characterize BsAbs is challenging. Developing bioassays for BsAbs requires a good understanding of the mechanism of action of the molecule, principles and applications of different bioanalytical methods, and phase-appropriate considerations per regulatory guidelines. Here, we review recent advances and case studies to provide strategies and insights for bioassay development for different types of bispecific molecules.
topic bispecific antibodies
bioassays
mechanisms of action
binding assays
potency assays
url https://www.mdpi.com/1422-0067/22/10/5350
work_keys_str_mv AT amescregister bioassaydevelopmentforbispecificantibodieschallengesandopportunities
AT somayehstarighat bioassaydevelopmentforbispecificantibodieschallengesandopportunities
AT hoyounglee bioassaydevelopmentforbispecificantibodieschallengesandopportunities
_version_ 1721414704596779008